Clinical Trials Directory

Trials / Completed

CompletedNCT00391105

Remifentanil Versus Morphine for Sedation of Premature Neonates With Respiratory Distress Syndrome

Comparative Study of the Use of Remifentanil Versus Morphine for Sedation and Analgesia of Premature Neonates During Mechanical Ventilation in the Treatment of Respiratory Distress Syndrome (RDS)

Status
Completed
Phase
Phase 4
Study type
Interventional
Enrollment
Sponsor
Federal University of Minas Gerais · Academic / Other
Sex
All
Age
60 Minutes – 28 Days
Healthy volunteers
Not accepted

Summary

In this randomised controlled study we intended to compared intubation conditions and the continuous infusion of remifentanil (n=10) and morphine (n=10) in mechanically ventilated premature neonates (28-34wk) regarding the time to be awake and, the time until extubation after interruption of the opioid administration.

Detailed description

Intubation and mechanical ventilation are majors component of intensive care for premature neonates with respiratory distress syndrome (RDS) and is associated with physiologic, biochemical, and clinical responses indicating pain and stress in prematures. Although morphine is one of the most used drugs for premedication and for sedation and analgesia during mechanical ventilation in the treatment of RDS its pharmacological profile precludes several limitations mostly due to its much delayed onset of action what makes the drug not suitable as premedication and due to its prolonged duration of action mainly in prematures. Unlike morphine, remifentanil has an unique pharmacokinetic properties with a rapid onset of action and, a fast decrease in plasma concentration after interruption of administration due to a context-sensitive half-time of 3.2 minutes. So, it could be the ideal opioid for neonates who are especially sensitive to respiratory depression by opioids

Conditions

Interventions

TypeNameDescription
DRUGRemifentanil

Timeline

Start date
2004-04-01
Completion
2005-11-01
First posted
2006-10-23
Last updated
2006-10-23

Source: ClinicalTrials.gov record NCT00391105. Inclusion in this directory is not an endorsement.